Neumora Therapeutics NMRA Stock
Neumora Therapeutics Price Chart
Neumora Therapeutics NMRA Financial and Trading Overview
| Neumora Therapeutics stock price | 1.74 USD |
| Previous Close | 1.85 USD |
| Open | 1.85 USD |
| Bid | 1.36 USD x 200 |
| Ask | 2.29 USD x 200 |
| Day's Range | 1.78 - 1.89 USD |
| 52 Week Range | 0.69 - 3.65 USD |
| Volume | 803.09K USD |
| Avg. Volume | 1.26M USD |
| Market Cap | 337.22M USD |
| Beta (5Y Monthly) | 3.051 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.91 USD |
NMRA Valuation Measures
| Enterprise Value | 225.64M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.0430157 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.0536914 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.956 |
Trading Information
Neumora Therapeutics Stock Price History
| Beta (5Y Monthly) | 3.051 |
| 52-Week Change | 147.32% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 3.65 USD |
| 52 Week Low | 0.69 USD |
| 50-Day Moving Average | 2.11 USD |
| 200-Day Moving Average | 2.2 USD |
NMRA Share Statistics
| Avg. Volume (3 month) | 1.26M USD |
| Avg. Daily Volume (10-Days) | 1.09M USD |
| Shares Outstanding | 185.28M |
| Float | 104.83M |
| Short Ratio | 3.78 |
| % Held by Insiders | 23.93% |
| % Held by Institutions | 55.89% |
| Shares Short | 4.47M |
| Short % of Float | 4.27% |
| Short % of Shares Outstanding | 2.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -58.10% |
| Return on Equity (ttm) | -121.21% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -235948000 USD |
| Net Income Avi to Common (ttm) | -236928000 USD |
| Diluted EPS (ttm) | -1.33 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 182.53M USD |
| Total Cash Per Share (mrq) | 1 USD |
| Total Debt (mrq) | 55.01M USD |
| Total Debt/Equity (mrq) | 52.96 USD |
| Current Ratio (mrq) | 5.872 |
| Book Value Per Share (mrq) | 0.596 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -206440000 USD |
| Levered Free Cash Flow (ttm) | -115712376 USD |
Profile of Neumora Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 260 Arsenal Place |
| ZIP | 02472 |
| Phone | 857 760 0900 |
| Website | https://www.neumoratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 96 |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Q&A For Neumora Therapeutics Stock
What is a current NMRA stock price?
Neumora Therapeutics NMRA stock price today per share is 1.74 USD.
How to purchase Neumora Therapeutics stock?
You can buy NMRA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neumora Therapeutics?
The stock symbol or ticker of Neumora Therapeutics is NMRA.
Which industry does the Neumora Therapeutics company belong to?
The Neumora Therapeutics industry is Biotechnology.
How many shares does Neumora Therapeutics have in circulation?
The max supply of Neumora Therapeutics shares is 185.28M.
What is Neumora Therapeutics Price to Earnings Ratio (PE Ratio)?
Neumora Therapeutics PE Ratio is now.
What was Neumora Therapeutics earnings per share over the trailing 12 months (TTM)?
Neumora Therapeutics EPS is -1.33 USD over the trailing 12 months.
Which sector does the Neumora Therapeutics company belong to?
The Neumora Therapeutics sector is Healthcare.